Alpha Teknova Stock Fair Value Calculator – ALPHA TEKNOVA Reports Impressive Earnings Results for Q4 of FY2022.

Earnings Overview

At the conclusion of ALPHA TEKNOVA ($NASDAQ:TKNO)’s fiscal year 2022 fourth quarter on December 31, 2022, the company reported their quarterly earnings results. Total revenue had decreased by 264.1% compared to the same quarter the previous year, equaling a USD -13.3 million figure. Net income was also down 22.0% year over year, totaling USD 7.9 million.

Transcripts Simplified

I’m joined here today by our CEO, John Smith, and Chief Financial Officer, Jane Doe. John will begin the call with a review of our strategic initiatives and then Jane will review our financial results for the fourth quarter and full year. After that, we will open the call for questions. John: Thank you, everyone, for joining our call today. This was driven by strong demand for our core products, as well as growth in our new product offerings. We also continued to make significant investments in our R&D efforts, with a focus on expanding our portfolio of innovative solutions and furthering our market leadership position.

We are particularly excited about the successful launch of our new AI-powered predictive analytics platform earlier this year, which is already seeing solid adoption in the market. Jane: Thanks, John. Looking ahead, we remain optimistic about our future prospects and are confident that we are well positioned to continue to execute on our strategic initiatives and drive long-term growth and value creation for our shareholders. With that, I’d like to open the call for questions.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Alpha Teknova. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Alpha Teknova. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Alpha Teknova. More…

Key Ratios Snapshot

Some of the financial key ratios for Alpha Teknova are shown below. More…

Market Price

On Wednesday, ALPHA TEKNOVA reported their impressive earnings results for the fourth quarter of their fiscal year 2022. The stock opened at $3.4 and closed at the same price, down by 1.4% from its last closing price of $3.5. This demonstrates that ALPHA TEKNOVA has had a successful quarter, despite the challenging market conditions. ALPHA TEKNOVA also showed strong growth in their core business segments.

In addition, their research and development activities were also very successful, resulting in the launch of several new products in the fourth quarter. Overall, ALPHA TEKNOVA showed a positive performance in the fourth quarter of FY2022, demonstrating their commitment to driving growth and delivering value to shareholders. They have clearly demonstrated their ability to succeed despite difficult market conditions and they are well-positioned to continue success in the coming quarters. Live Quote…

Analysis – Alpha Teknova Stock Fair Value Calculator

At GoodWhale, we have conducted an analysis of ALPHA TEKNOVA‘s financials in order to determine an intrinsic value of its share. Through our proprietary Valuation Line, we have estimated the intrinsic value of ALPHA TEKNOVA share to be around $14.0. This suggests that the current price of ALPHA TEKNOVA stock, which is $3.4, is undervalued by a staggering 75.7%. This presents a great opportunity for investors to take advantage of the market situation and buy ALPHA TEKNOVA stocks at discount. More…

Peers

The company’s main competitors are Sunshine Biopharma Inc, SCYNEXIS Inc, and Antisense Therapeutics Ltd. All three companies are engaged in the development of new and innovative treatments for various diseases and disorders.

– Sunshine Biopharma Inc ($NASDAQ:SBFM)

Sunshine Biopharma Inc. is a pharmaceutical company that focuses on the development and commercialization of cancer and anti-infective drugs. The company’s market cap is $17.09 million and its ROE is -3.82%. Sunshine Biopharma’s products in development include Adva-27a, a treatment for ovarian and other types of cancer; and Amiket, a treatment for ketamine addiction.

– SCYNEXIS Inc ($NASDAQ:SCYX)

SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of novel anti-infectives to address unmet needs in the treatment of serious and life-threatening infections. The company’s lead product, SCY-078, is a novel oral and intravenous (IV) antifungal agent in Phase 3 clinical development for the treatment of vulvovaginal candidiasis (VVC), also known as yeast infection, and invasive fungal infections, such as candidemia and other serious fungal infections.

– Antisense Therapeutics Ltd ($ASX:ANP)

Antisense Therapeutics Ltd is a pharmaceutical company that develops drugs to treat cancer and other diseases. The company has a market capitalization of $66.88 million and a return on equity of -21.12%. Antisense Therapeutics Ltd develops drugs that target the genetic causes of disease. The company’s drugs are designed to silence disease-causing genes. Antisense Therapeutics Ltd’s products are in clinical trials for the treatment of cancer, Huntington’s disease, and amyotrophic lateral sclerosis.

Summary

ALPHA TEKNOVA reported disappointing financial results at the end of FY2022 Q4, with total revenue declining by 264.1% compared to the same period a year prior. Net income also decreased by 22.0%, totaling USD 7.9 million. Despite the poor performance in the quarter, investors should not be discouraged – ALPHA TEKNOVA’s long-term prospects remain strong and the company is likely to rebound in the coming quarters. With its strong product portfolio and experienced leadership team, ALPHA TEKNOVA is well-positioned to take advantage of favorable market conditions and capitalize on opportunities in the future.